nach oben

European Journal of Clinical Microbiology & Infectious Diseases

28.02.2024 | Brief Report

Successful treatment of sino-pulmonary infection & skull base osteomyelitis caused by New Delhi metallo-β-lactamase-producing Pseudomonas aeruginosa in a renal transplant recipient by using an investigational antibiotic cefepime/zidebactam (WCK 5222)

verfasst von: Rajeev Soman, Rasika Sirsat, Ayesha Sunavala, Neha Punatar, Jugal Mehta, Camilla Rodrigues, Balaji Veeraraghavan

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases

Einloggen, um Zugang zu erhalten

Abstract

A case of sino-pulmonary infection with skull base osteomyelitis due to XDR-Pseudomonas aeruginosa in renal transplant recipient was successfully treated with investigational antibiotic, cefepime/zidebactam (WCK 5222). This case highlights challenges in managing XDR-pseudomonal infection where source control was infeasible, antibiotic options were extremely limited and individualized dose adjustments were needed.

Karlowsky JA, Hackel MA, Bouchillon SK, Sahm DF (2020) In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-negative Bacilli not susceptible to Carbapenems. Antimicrob Agents Chemother 64(12):e01432–e01420CrossRefPubMedPubMedCentral

Lee YL, Hsueh PR (2023) Poor in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam against carbapenem-resistant Pseudomonas aeruginosa in India: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018–2021. J Infect 87(1):e1–e4CrossRefPubMed

Shanthi M, Sekar U, Kamalanathan A, Sekar B (2014) Detection of New Delhi metallo beta lactamase-1 (NDM-1) carbapenemase in Pseudomonas aeruginosa in a single centre in southern India. Indian J Med Res 140:546–550PubMedPubMedCentral

Jorth P, McLean K, Ratjen A, Secor PR, Bautista GE, Ravishankar S et al (2017) Evolved Aztreonam Resistance is multifactorial and can produce hypervirulence in Pseudomonas aeruginosa. mBio 8(5):e00517–e00517CrossRefPubMedPubMedCentral

Timsit JF, Paul M, Shields RK, Echols R, Baba T, Yamano Y et al (2022) Cefiderocol for the Treatment of Infections due to Metallo-B-lactamase-producing pathogens in the CREDIBLE-CR and APEKS-NP phase 3 Randomized studies. Clin Infect Dis 75(6):1081–1084CrossRefPubMedPubMedCentral

Katsube T, Nicolau DP, Rodvold KA, Wunderink RG, Echols R, Matsunaga Y et al (2021) Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia. J Antimicrob Chemother 76(11):2902–2905CrossRefPubMedPubMedCentral

Mushtaq S, Sadouki Z, Vickers A, Livermore DM, Woodford N (2020) Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-negative Bacteria. Antimicrob Agents Chemother 64(12):e01582–e01520CrossRefPubMedPubMedCentral

Simner PJ, Mostafa HH, Bergman Y, Ante M, Tekle T, Adebayo A et al (2022) Progressive Development of Cefiderocol Resistance in Escherichia coli during Therapy is Associated with an increase in blaNDM-5 Copy Number and Gene expression. Clin Infect Dis 75(1):47–54CrossRefPubMed

Mushtaq S, Vickers A, Doumith M, Ellington MJ, Woodford N, Livermore DM (2021) Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 76(1):160–170CrossRefPubMed

10.

Moya B, Bhagwat S, Cabot G, Bou G, Patel M, Oliver A (2020) Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa. J Antimicrob Chemother 75(6):1474–1478CrossRefPubMed

11.

Hujer AM, Marshall SH, Mack AR, Hujer KM, Bakthavatchalam YD, Umarkar K, Palwe SR, Takalkar S, Joshi PR, Shrivastava R, Periasamy H, Bhagwat SS, Patel MV, Veeraraghavan B, Bonomo RA (2023) Transcending the challenge of evolving resistance mechanisms in Pseudomonas aeruginosa through β-lactam-enhancer-mechanism-based cefepime/zidebactam. mBio 14:e01118–e01123CrossRefPubMedPubMedCentral

12.

Kidd JM, Abdelraouf K, Nicolau DP (2020) Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model. J Antimicrob Chemother 75(1):149–155PubMed

13.

Tirlangi PK, Wanve BS, Dubbudu RR, Yadav BS, Kumar LS, Gupta A et al (2023) Successful use of Cefepime-Zidebactam (WCK 5222) as a salvage therapy for the treatment of disseminated extensively drug-resistant New Delhi Metallo-β-Lactamase-producing Pseudomonas aeruginosa infection in an adult patient with Acute T-Cell Leukemia. Antimicrob Agents Chemother 67(8):e0050023CrossRefPubMed

14.

Dubey D, Roy M, Shah TH, Bano N, Kulshrestha V, Mitra S et al (2023) Compassionate use of a novel β-lactam enhancer-based investigational antibiotic cefepime/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: a case report. Ann Clin Microbiol Antimicrob 22(1):55CrossRefPubMedPubMedCentral

Titel: Successful treatment of sino-pulmonary infection & skull base osteomyelitis caused by New Delhi metallo-β-lactamase-producing Pseudomonas aeruginosa in a renal transplant recipient by using an investigational antibiotic cefepime/zidebactam (WCK 5222)
verfasst von: Rajeev Soman
Rasika Sirsat
Ayesha Sunavala
Neha Punatar
Jugal Mehta
Camilla Rodrigues
Balaji Veeraraghavan
Publikationsdatum: 28.02.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-024-04791-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Successful treatment of sino-pulmonary infection & skull base osteomyelitis caused by New Delhi metallo-β-lactamase-producing Pseudomonas aeruginosa in a renal transplant recipient by using an investigational antibiotic cefepime/zidebactam (WCK 5222)

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin